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Brief Definitive Report

Potential role of orexin and sleep
modulation in the pathogenesis of
Alzheimer’s disease

The Journal of Experimental Medicine
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Age-related aggregation of amyloid- (A) is an upstream pathological event in Alzheimer’s
disease (AD) pathogenesis, and it disrupts the sleep–wake cycle. The amount of sleep
declines with aging and to a greater extent in AD. Poor sleep quality and insufficient
amounts of sleep have been noted in humans with preclinical evidence of AD. However,
how the amount and quality of sleep affects A aggregation is not yet well understood.
Orexins (hypocretins) initiate and maintain wakefulness, and loss of orexin-producing
neurons causes narcolepsy. We tried to determine whether orexin release or secondary
changes in sleep via orexin modulation affect A pathology. Amyloid precursor protein (APP)/
Presenilin 1 (PS1) transgenic mice, in which the orexin gene is knocked out, showed a
marked decrease in the amount of A pathology in the brain with an increase in sleep
time. Focal overexpression of orexin in the hippocampus in APP/PS1 mice did not alter the
total amount of sleep/wakefulness and the amount of A pathology. In contrast, sleep
deprivation or increasing wakefulness by rescue of orexinergic neurons in APP/PS1 mice
lacking orexin increased the amount of A pathology in the brain. Collectively, modulation
of orexin and its effects on sleep appear to modulate A pathology in the brain.

CORRESPONDENCE
David M. Holtzman:
holtzman@neuro.wustl.edu
Abbreviations used: A,
amyloid-; AD, Alzheimer’s
disease; APP, amyloid precursor
protein; CSF, cerebrospinal
fluid; EEG, electroencephalogram; EMG, electromyogram;
GFAP, glial fibrillary acidic
protein; ISF, interstitial fluid.

Age-related aggregation of amyloid- (A) is
an upstream pathological event in Alzheimer’s
disease (AD) pathogenesis (Holtzman et al., 2011;
Sperling et al., 2011). As the accumulation and
aggregation of A in the brain is known to develop 10–15 yr before the initial symptoms
of AD, understanding the factors that lead to
A aggregation are likely to be important in delaying the onset of this pathology and delaying/
preventing AD (Holtzman et al., 2011; Sperling
et al., 2011). Diverse lines of in vitro and in vivo
studies have shown that synaptic activity and
specifically synaptic vesicle release is coupled with
presynaptic A release (Kamenetz et al., 2003;
Cirrito et al., 2008; Bero et al., 2011; Roh et al.,
2012). In addition, sleep plays a role in the regulation of synaptic weight in the brain such that
sleep appears to downscale the slow wave activity of the brain caused by accumulated load
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of synaptic potentiation during wakefulness
(Vyazovskiy et al., 2009). Poor sleep quality and
insufficient amounts of sleep have been noted
in humans with preclinical evidence of AD (Roh
et al., 2012; Ju and Holtzman, 2013; Ju et al.,
2014). These observations suggest that understanding how integrated synaptic and network
activity as measured by the sleep–wake cycle
regulates A may provide novel insights into
AD pathogenesis. However, how the amount
and quality of sleep affect A aggregation is not
yet well understood (Ju et al., 2014). Orexins
(hypocretins) initiate and maintain wakefulness,
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Figure 1. Marked reduction of A pathology in the APP/PS1/OR/ mice compared with APP/PS1 mice. (A–I) The amount of A pathology
was noted at 3.5 (A–C) and 8.5 mo (D–F) in APP/PS1-21 mouse line and at 6 mo in APP/PS1E9 mouse line (G–I). (J and K) Amount of wakefulness at
3 mo of age before the onset of A pathology in the brain was compared between APP/PS1E9 and APP/PS1E9/OR/ mice. Each mouse was investigated independently one time. Data are presented as mean ± SEM (n = 4–12 in each group, two-tailed Student’s t test in C, F, and I and Mann-Whitney
test in J). *, P < 0.05; **, P < 0.01; and ***, P < 0.001. Bar, 500 µm.
2488
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and loss of orexin-producing neurons causes narcolepsy
(de Lecea et al., 1998; Chemelli et al., 1999).
Levels of soluble A in the extracellular interstitial fluid
(ISF) of the hippocampus in mice are dynamically and positively associated with minutes awake per hour and negatively
associated with time asleep (Kang et al., 2009). In addition,
the sleep–wake cycle also affects the A pathology in the brain.
A study in mice showed that intracerebral administration of
orexin can acutely increase both wakefulness and A levels
and systemic treatment with an orexin receptor antagonist
decreased A deposition in amyloid precursor protein (APP)
transgenic mouse models (Kang et al., 2009). Pharmacological experiments suggest that orexin and the sleep–wake cycle
appear to be related to regulation of A levels. We sought to
determine for the first time whether genetic manipulation of
orexin has similar effects as pharmacological manipulation and,
importantly, whether orexin is influencing A levels and A
pathology directly via orexin signaling or indirectly via its effects on the sleep–wake cycle.
JEM Vol. 211, No. 13

RESULTS AND DISCUSSION
Marked reduction of A pathology in the
APP/Presenilin 1 (PS1)/Orexin knockout (OR/) mice
To more specifically address the role of orexin in regulating
A levels and pathology, we used APP/PS1-21 transgenic mice
(Radde et al., 2006), which begin to develop A deposition
at 2 mo of age, and bred them to OR/ mice (de Lecea
et al., 1998; Chemelli et al., 1999). When orexin was knocked
out in APP/PS1-21 mice (APP/PS1-21/OR/ mice), there
was a marked reduction of A plaque pathology at 3.5 mo as
well as at 8.5 mo of age compared with APP/PS1-21 mice
(Fig. 1, A–F). Similar patterns of reduction in A deposition
were also seen when orexin was knocked out in another
mouse model that develops A deposition, APP/PS1E9 mice
( Jankowsky et al., 2004), which begin to develop A deposition
at 4 mo of age. APP/PS1E9/OR/ mice had a marked reduction in A deposition at 6 mo of age compared with APP/
PS1E9 mice expressing orexin (Fig. 1, G–I). APP/PS1E9/
OR/ mice demonstrated significantly decreased wakefulness
2489
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Figure 2. Marked reduction of amyloid pathology in the APP/PS1/OR/ mice compared with APP/PS1 mice. (A–L) Amyloid pathology measured by A immunoreactivity and number of amyloid plaques after X-34 staining is noted at 3.5 (A, B, G, and H) and 8.5 mo (C, D, I, and J) in the APP/
PS1-21 mouse line and at 6 mo in the APP/PS1E9 mouse line (E, F, K, and L). Each mouse was investigated independently one time. Data are presented as
mean ± SEM (n = 5–9 in each group, two-tailed Student’s t test). *, P < 0.05; **, P < 0.01; and ***, P < 0.001. Bar, 100 µm.

by 11.5% during the 12-h dark phase at 3 mo of age compared
with mice expressing orexin, before the onset of A pathology in the brain (Fig. 1, J and K). The difference in wakefulness was more prominent during the early phases of the dark
period (6 p.m. to 12 a.m. with an 18.3% difference). Fibrillar
A deposition assessed by X-34 staining was also markedly
reduced in the brains of APP/PS1-21/OR/ mice and APP/
PS1E9/OR/ mice compared with mice expressing orexin
(Fig. 2). We also assessed A levels biochemically. The total
amount of both A40 and A42 solubilized by 5M guanidine
was also significantly reduced in the hippocampus as well as
in the cortex in APP/PS1-21/OR/ mice compared with
APP/PS1-21 mice. Similar patterns of pathological A reduction were also noted in APP/PS1E9/OR/ mice compared with APP/PS1E9 mice (Fig. 3).
Reversal of A pathology by modulation of sleep
rather than focal overexpression of orexin
Orexin receptors are present on hippocampal neurons, so we
focally overexpressed orexin by stereotaxic injection of a lenti
viral vector expressing orexin into the hippocampus of APP/
PS1E9 mice to determine whether local orexin signaling was
directly leading to the effects observed on A deposition. This
treatment resulted in no changes in levels of A deposition in
the brain nor changes in sleep time despite focal increases in the
level of orexin in the hippocampus (Fig. 4). To further investigate
whether the reduction in A pathology in orexin knockout
mice is mainly caused by the effects of orexin signaling on sleep,
expression of orexin specifically in orexinergic neurons was
2490

instituted in 1.5-mo-old APP/PS1-21/OR/ mice. We used
an orexin lentiviral vector in which orexin is driven by the hypocretin/orexin promoter. After injection of this vector bilaterally
in the hypothalamus, expression of orexin in orexinergic neurons
was restored (Fig. 5 F). 6 wk after injection with the hypocretin
promoter–driven orexin lentiviral vector, APP/PS1-21/OR/
mice had a significantly increased amount of wakefulness as
well as increased amount of A deposition in the hippocampus
and cortex compared with mice injected with a control vector
(Figs. 5 E and 6). Collectively, results from focal and generalized
orexin expression in different brain regions using different promoters strongly support the idea that the reduction in A pathology noted in APP/PS1/OR/ mouse models is caused by
secondary changes in sleep time induced by hypothalamic expression of orexin rather than by alteration in orexin signaling
in hippocampus and other brain regions.
We also analyzed the functional effect of APP/PS1/OR/
mice in which orexin expression was rescued in orexinergic
neurons by measuring the diurnal fluctuation of A in the
extracellular space using in vivo microdialysis. In APP/PS121/OR/ mice injected with a lentiviral vector in which
the hypocretin/orexin promoter is driving orexin expression
bilaterally in the hypothalamus, restoration of diurnal fluctuation of ISF Ax-40 was found, suggesting possible functional
rescue of orexinergic neurons in the hypothalamus bilaterally
(Fig. 5, A–D). There was, however, no difference in the amplitude of circadian rhythms assessed by cosinor analysis between the groups (Fig. 5, C and D). This is likely caused by
the number of mice used in this experiment.
Role of orexin and sleep in Alzheimer’s disease | Roh et al.
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Figure 3. Strong reduction in A species in APP/PS1 mice lacking orexin. (A–D) The amount of PBS-soluble and guanidine-soluble forms of
A40 and A42 were compared in APP/PS1E9/OR/ and APP/PS1E9 mice (left two columns) and in APP/PS1-21/OR/ and APP/PS1-21 mice (right
two columns). Results were obtained from the hippocampus (A and B) and from the cortex (C and D) of each group of mice. Each mouse was investigated
independently one time. All samples were measured in triplicate. Data are presented as mean ± SEM (n = 5–9 in each group, two-tailed Student’s t test).
*, P < 0.05; **, P < 0.01; and ***, P < 0.001.
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Sleep deprivation induced A pathology in OR/ mice
Finally, we wanted to determine whether sleep deprivation
increased A deposition in the absence of orexin, as previously observed in the presence of orexin (Kang et al., 2009).
We sleep-deprived APP/PS1-21/OR/ mice using the
platform above water method as previously described (Kang
et al., 2009). Interestingly, relative to mice that were placed
on a large platform for 20 h per day for 3 wk, where they can
maintain a normal sleep–wake cycle, mice placed on a small
platform that experienced sleep deprivation had a significant
increase in A plaque pathology (Fig. 7). Collectively, these
findings strongly support the idea that the amount of sleep, as
modulated by hypothalamic but not local orexin signaling, is
crucial in regulating A metabolism and AD pathogenesis.
Increasing evidence suggests that neuronal activity in many
brain regions is physiologically regulated by the sleep–wake
cycle (Bero et al., 2011). It has been noted in animals that
JEM Vol. 211, No. 13

decreases in sleep time and increases in amount of A levels
and deposition have a reciprocal relationship (Kang et al., 2009;
Roh et al., 2012; Ju et al., 2014). Intriguingly, recent results
from humans also indicate that the quality or amount of sleep
is inversely associated with the amount of A measured in
the cerebrospinal fluid (CSF; Ju and Holtzman, 2013; Ooms
et al., 2014) and that the amount of sleep inversely correlates
with fibrillar forms of A quantified by amyloid PET scan
(Spira et al., 2013). Treatment with active vaccination with
A42 prevented development of A pathology and abnormalities of the sleep–wake cycle in APP/PS1E9 mice (Roh
et al., 2012). This demonstrated that A aggregation and accumulation caused a sleep abnormality. In this study, the opposite is also true, i.e., an increase in sleep time caused by orexin
deficiency resulted in a decrease in the amount of A pathology that developed in the brain. Collectively, these findings suggest that increasing certain types of sleep should be considered
2491
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Figure 4. No changes in A deposition and amount of wakefulness by focal overexpression of orexin. (A–F) Amount of A pathology
was compared after focal injection of ubiquitin-driven orexin lentiviral vector versus ubiquitin-driven GFP lentiviral vector in the hippocampus
from 3 to 6 mo (A–C) or 5 to 9 mo (D–F) in APP/PS1E9 mice. (G) Levels of orexin in the hippocampus and CSF were compared after focal injection
of orexin or GFP lentiviral vector driven by ubiquitin promoter. (H) The amount of wakefulness in APP/PS1E9 mice was compared after focal injection of ubiquitin-driven orexin lentiviral vector versus ubiquitin-driven GFP lentiviral vector. Each mouse was investigated independently one time.
Data are presented as mean ± SEM (n = 4–5 in each group, two-tailed Student’s t test in C, F, and H; one-way ANOVA, followed by Tukey’s post
hoc test in G). *, P < 0.05. Bar, 500 µm.

as a therapeutic target to decrease A-associated AD pathogenesis. Possible side effects of sleep induction such as excessive
daytime sleepiness or cataplexy driven by knocking out or
decreasing orexin function need to be considered in the process of designing new therapeutic interventions targeting sleep.
It is notable that a 12% increase in the sleep time during
the dark phase was associated with >50% reduction in the development of A pathology in the brain. This matches well
with the previous findings that an 15% decrease in the amount
of soluble forms of A in the extracellular space resulted in
an up to 50% reduction of A plaque growth and formation
in the brain (Yan et al., 2009). It suggests that a small increase
in NREM sleep or small improvement in sleep quality and
the resulting decrease in A release into the extracellular space
could be beneficial for the delay or attenuation of emergence
of A-associated pathologies in AD. Although our data support a mechanism whereby decreased neuronal activity during
sleep results in a decrease in ISF A, we cannot yet rule out
the contribution of increased A clearance from the ISF as
2492

proposed by Xie et al. (2013). It will be important in future
experiments to determine whether different methods of sleep
or orexin modulation will trigger new methods of intervention targeting A pathophysiology in the brain. Given the association between neuronal activity and release of tau in the
brain, further studies to determine whether the sleep–wake cycle
also influences this key molecule in the pathogenesis of AD
and other neurodegenerative diseases will be critical (Yamada
et al., 2014). It is important to note that other systems involved
in the sleep–wake cycle are also likely to affect the pathophysiology of AD. Even though we concluded that not orexin itself
but rather the secondary changes in the sleep–wake cycle affect
AD pathophysiology in brains of mice, modulation of other
molecules that increase or decrease wakefulness such as noradrenergic and GABAergic modulation are also likely to influence
AD pathophysiology (Matsuki et al., 2009; Carter et. al, 2010).
The location of A deposition in the human brain overlaps
very closely with a brain network called the “default mode”
network, which is made up of brain regions that appear to have
Role of orexin and sleep in Alzheimer’s disease | Roh et al.
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Figure 5. Restoration of diurnal fluctuation of ISF A40 via rescue of orexin expression in APP/PS1/OR/ mice. (A and B) Diurnal fluctuation
of ISF A40 in young APP/PS1E9 mice was compared with the diurnal fluctuation in the same mice when orexin was knocked out (APP/PS1E9/OR/
mice). (C–E) Diurnal fluctuation of ISF A40 in the hippocampus and minutes awake per hour of APP/PS1-21/OR/ mice treated with hypocretin/orexin
promoter–driven lentiviral vector overexpressing orexin in the hypothalamus bilaterally were compared with mice treated with the same lentiviral vector
expressing GFP. (F) Expression of orexin by immunostaining in orexinergic neurons in the hypothalamus of APP/PS1-21/OR/ mice treated with hypocretin/
orexin promoter–driven lentiviral vector expressing GFP or orexin (middle and right) compared with wild-type mice (left). Each mouse was investigated
independently one time. All ISF A measurements were performed in duplicate. Data are presented as mean ± SEM (n = 6 in each group, two-tailed Student’s t test in A–D and Mann–Whitney test in E). *, P < 0.05; and **, P < 0.01. Bar, 100 µm.
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the highest measures of aerobic glycolysis when individuals are
at rest (Raichle et al., 2001; Vlassenko et al., 2010). In addition
to the global reduction in neuronal activity resulting from an increase in sleep time as shown here, focal alteration of brain
activity, connectivity, or even focal sleep modulation through
pharmacologic or other methods may also merit consideration
as potential therapies in AD and other neurodegenerative disorders (Nir et al., 2011; Vyazovskiy et al., 2011). Such manipulation may be a powerful way to modulate A levels and
pathology by taking advantage of normal brain physiology.
MATERIALS AND METHODS
Mice. All experiments were approved by the Animal Studies Committee
at Washington University in St. Louis. Female APPswe/PS1E9 mice on a
B6 background (The Jackson Laboratory) were crossed with OR/ mice on
a C57BL/6 background to produce APPswe/PS1E9 hemizygous/OR+/ mice.
Then, APPswe/PS1E9; OR+/ mice were crossed with OR/ mice to obtain APPswe/PS1E9 hemizygous OR/ mice (APPswe/PS1E9/OR/).
APP/PS1-21/OR/ mice were obtained using the same methods beginning from crossing the APP/PS1-21 mice (C57BL/6) with OR/ mice
(C57BL/6). APP/PS1-21 mice (C57BL/6) were provided by M. Jucker at
the University of Tubingen (Tubingen, Germany).
ELISA. Microdialysis samples were analyzed for Ax-40, Ax-42, or A1-x
with sandwich ELISAs. In brief, Ax-40, Ax-42, and A1-x were captured
with monoclonal antibodies targeted against amino acids 35–40 (HJ2; Cirrito
et al., 2003), 37–42 (HJ7.4; Roh et al., 2012), and 13–28 (m266; Cirrito et al.,
2003) of A, respectively. For Ax-40 and Ax-42 assays, a biotinylated central domain monoclonal antibody (HJ5.1; Koenigsknecht-Talboo et al., 2008)
followed by streptavidin–poly-HRP40 (Fitzgerald) was used for detection.
JEM Vol. 211, No. 13

For A1-x assays, a biotinylated N-terminal domain monoclonal antibody
(3D6; Koenigsknecht-Talboo et al., 2008) followed by streptavidin–
poly-HRP20 (Fitzgerald) was used. The antibodies m266 and 3D6 were gifts
from Eli Lilly. All assays were developed with Super Slow ELISA TMB
(Sigma-Aldrich) and read on a Bio-Tek Synergy 2 plate reader at 650 nm. Hippocampal tissue lysates were analyzed for A1-40 and A1-42 using a denaturing, sandwich ELISA specific for human A1-40 and A1-42 after solubilizing
the tissue in 5M guanidine as previously described (Cirrito et al., 2003).
Sleep–wake monitoring. Polysomnographic sleep–wake cycle analysis of
mice was performed as described previously (Bero et al., 2011; Roh et al.,
2012). In brief, electroencephalogram (EEG) and electromyogram (EMG)
electrodes were implanted simultaneously with a microdialysis guide cannula.
For EEG recording, two stainless steel screws attached to wire electrodes were
placed over the right frontal bone (bregma +1.0 mm, 1.5 mm lateral to midline) and the right parietal bone (bregma 3.0 mm, 2.5 mm lateral to midline).
Two wire electrodes were directly inserted into the neck musculature for EMG
recording.The ground electrode was placed on the skull over the cerebellum.
Insulated leads from the EEG and EMG electrodes were soldered to a miniconnector. After surgery, mice were housed in 12-h light/12-h dark for 2 wk
before recording began. To monitor the sleep–wake cycle, we transferred the
mice to recording cages maintained in 12-h light/12-h dark conditions (light
phase began at 6 a.m.), and we connected the mini-connector to flexible recording cables. Mice were habituated to the recording cages for 3 d. At the
end of the habituation period, EEG and EMG recording began simultaneously
with collection of microdialysis samples. EEG and EMG signals were displayed on a monitor and stored in a computer for analysis of sleep states. EEG
and EMG recordings were assessed with a P511K AC preamplifier (GrassTelefactor Instruments), digitized with a DigiData 1440A Data Acquisition
System (Molecular Devices), and recorded digitally with pCLAMP 10.2
(Molecular Devices). EEG and EMG signals were filtered (EEG: high pass
1 Hz, low pass 30 Hz; EMG: high pass 10 Hz, low pass 100 Hz) and used to
2493
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Figure 6. Increase in A deposition and wakefulness by rescue of orexin expression in APP/PS1/OR/ mice via expression of orexin with
lentiviral vector driven by hypocretin/orexin promoter in the bilateral hypothalamus. (A–C) Amount of A pathology in the hippocampus and
cortex of the APP/PS1-21/OR/ mice after bilateral injection of hypocretin promoter–driven orexin lentiviral vector in the hypothalamus of the APP/PS1/
OR/ mice was compared with results from injection of the same lentiviral vector overexpressing GFP. (D) The amount of wakefulness as measured by
polysomnography was compared between the same groups of mice. Each mouse was investigated independently one time. Data are presented as mean ±
SEM (n = 6–7 in each group, two-tailed Student’s t test in C; n = 3 in each group, Mann–Whitney test in D). *, P < 0.05. Bar, 500 µm.

identify vigilance states. EEG and EMG recordings were scored semiautomatically with sleep-scoring software (SleepSign; Kissei Comtec Co. Ltd.)
and binned into 10-s epochs as wakefulness, REM sleep, and NREM sleep
on the basis of standard criteria of rodent sleep. Semiautomatic sleep scoring
was visually inspected and corrected when appropriate.The automatic analysis and visual inspection was performed in a blinded state to the genotype and
age of mice. Chronic sleep deprivation was performed as previously described
(Kang et al., 2009).

Plaque deposition analyses. After mice were perfused with PBS transcardially, brains were removed, fixed in 4% paraformaldehyde for 24 h (4°C),
cryoprotected with 30% sucrose in PBS (4°C), frozen in powdered dry ice,
and cut on a freezing sliding microtome. Serial coronal sections (50 µm thick)
were collected from the genu of the corpus callosum to caudal hippocampus.
Sections (each separated by 300 µm) were stained with biotinylated HJ3.4
(A 1–13) antibody to visualize A-immunopositive plaques or X-34 dye to
visualize fibrillar amyloid plaques (Roh et al., 2012). Immunostained sections
and X-34–stained sections were imaged with a NanoZoomer slide scanner
(Hamamatsu Photonics). Quantitative analysis of percent area covered by
HJ3.4- or X-34–positive staining was performed using a neurostereological
method as described previously (Kim et al., 2009). In brief, images of immuno
stained sections were exported with NDP viewer software (Hamamatsu
Photonics), converted to 8-bit grayscale with ACDSeePro 2 software (ACD
Systems), thresholded to highlight A-specific staining, and analyzed with
ImageJ software (National Institutes of Health). Images of X-34–stained sections were converted to 16-bit grayscale, thresholded to highlight X-34–
specific staining, and analyzed with ImageJ software.A mouse brain atlas was used
to identify hippocampal sections relative to bregma (1.7, 2.0, 2.3 mm)
2494

for quantitative analysis of immuno- and X-34–positive staining as described
previously (Roh et al., 2012).
Overexpression of orexin by lentiviral vector and measurement of
orexin. Lentiviral vectors were prepared in the Hope Center Viral Vectors
Core. For focal overexpression of orexin, orexin or GFP driven by an ubiquitin promoter was overexpressed via lentivirus in the hippocampus bilaterally in APPswe/PS1E9 mice (B6C3) starting at 5 mo of age, and the amount
of sleep and A pathology from both groups were compared at 9 mo. To
investigate the effect of focal overexpression of orexin before A plaque pathology was formed in the hippocampus, the same lentiviral injection experiments were performed in APPswe/PS1E9 mice (B6C3) with viral injection
at 3 mo and pathological assessment at 6 mo. For rescue of orexinergic neurons, orexin or GFP driven by an hypocretin/orexin promoter was expressed
via lentivirus in the bilateral hypothalamus in APPswe/PS1-21/Orexin
knockout mice (C57BL/6) starting at 1.5 mo of age, and the amount of sleep
and A pathology from both groups were compared at 3 mo. The mouse
hypocretin/orexin promoter was provided by L. de Lecea. Brains were sectioned on a freezing microtome at 50-µm thickness. Floating brain sections
at a 1:6 series were processed for anti–orexin-A and anti–glial fibrillary acidic
protein (GFAP) immunohistochemistry as follows: tissue was washed in Trisbuffered saline (TBS), then quenched in 3% hydrogen peroxide solution for
10 min, washed again in TBS, and then incubated in 0.25% Triton-X solution
plus 5% normal goat serum for 30 min. Finally, the slides were incubated in
primary antibody plus 5% normal goat serum, anti–orexin-A at 1:10,000 overnight (rabbit anti–mouse Orexin-A; Phoenix Pharmaceuticals, Inc.) or antiGFAP at 1:1,000 (polyclonal chicken anti-GFAP; EMD Millipore). The next
day, sections were incubated in a solution containing goat anti–rabbit IgG biotinylated secondary antibody for orexin or donkey anti–chicken secondary
Role of orexin and sleep in Alzheimer’s disease | Roh et al.
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Figure 7. Increased A deposition with chronic sleep deprivation in APP/PS1-21/OR/ mice. (A–F) The amount of A plaques stained with
HJ3.4B (A–C) and fibrillar A stained with X-34 (D–F) were compared between APP/PS1-21/OR/ mice exposed to a large platform and a small platform.
Sleep deprivation experiments were performed using a small and large platform in a cage with water on the bottom, where a mouse cannot sleep on the
small platform because of its size, whereas they can maintain a normal sleep–wake cycle on the larger platform. Mice exposed to small platforms (n = 3)
and to large platforms (n = 3) were analyzed together within a set of experiments. The results are the sum of five repeats in different mice. Each mouse
was investigated independently. Data are presented as mean ± SEM (n = 13–14 in each group, two-tailed Student’s t test). *, P < 0.05; and **, P < 0.01.
Bars: (A) 500 µm; (D) 100 µm.

Br ief Definitive Repor t

antibody for GFAP at 1:1,000 dilution, and signal was then amplified using
the Vectastain ABC kit at 1:400 (Vector Laboratories) followed by visualization
with DAB-nickel. Sections were carefully mounted onto glass microscope
slides, air-dried, and then dehydrated in ascending ethanols and coverslipped
with Cytoseal. CSF and brain tissue lysate samples were analyzed for orexin-A
(human, rat, mouse, porcine, bovine, and ovine) levels using a commercially
available fluorescent enzymatic immunoassay (EIA) kit (Phoenix Pharmaceuticals). All samples were assayed in duplicate, and the mean of the two values was reported.

Statistical analysis. Statistical significance was determined by two-tailed
Student’s t test if the datasets fulfilled the normality test (Kolmogorov–Smirnov
test). When the dataset did not meet the assumptions of a parametric test,
Mann–Whitney rank sum test was performed. One-way ANOVA followed
by Tukey’s post hoc test for multiple comparisons was performed if the datasets
fulfilled the equal variance test (Levene’s test) and normality test (Kolmogorov–
Smirnov test). All statistical analyses were performed with Prism version 4.0
for Windows (GraphPad Software) and SPSS 15.0 for Windows (SPSS Inc.).
Values were accepted as significant if P < 0.05.
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